Autopsy report · NCT00751036
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg
Cause of deathNo reason given
Life of this trial
- Registered 9 months before it started.
- Ran for about 3 years 2 months before it stopped.
- 94 participants enrolled.
- Results were posted on the registry 1 year 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Nilotinib; Imatinib
- Participants
- 94
- Sites
- 32
- Countries
- Argentina, Brazil, Canada, China, Mexico, Russia, South Korea, Thailand, Venezuela
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.